Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...

Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy.

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Shares of AbbVie Inc. ABBV slid 1.47% to $171.35 Wednesday, on what proved to be an all-around positive trading session for ...

AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?

Bitcoin, XRP and other cryptocurrencies are rising in price early Tuesday. The world’s largest digital coin, Bitcoin, is up 5.4% over the last 24 hours to last trade at $96,564 according to CoinDesk ...

Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected ...

AbbVie (ABBV) and Regenxbio (RGNX) announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet Age-Related Macular ...

Here are some key corporate results, economic data releases and other events to watch for this week: Monday The four-day ...

The Motley Fool has positions in and recommends AbbVie, Bristol Myers Squibb, Cisco Systems, Pfizer, and Texas Instruments. The Motley Fool recommends Amgen and Verizon Communications. The Motley Fool ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising ...